Reata Pharms Drug Patent Portfolio
Reata Pharms owns 1 orange book drug protected by 7 US patents Given below is the list of Reata Pharms's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8993640 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | 24 Apr, 2033 | Active |
US9701709 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | 24 Apr, 2033 | Active |
US8124799 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | 03 Dec, 2029 | Active |
US11091430 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 | 20 Apr, 2029 | Active |
US11919838 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | 20 Apr, 2029 | Active |
US8440854 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 | 20 Apr, 2029 | Active |
US9670147 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | 20 Apr, 2029 | Active |
Latest Legal Activities on Reata Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Reata Pharms.
Activity | Date | Patent Number |
---|---|---|
Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US8993640 |
Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US8440854 |
Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US9701709 |
Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US8124799 |
Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US9670147 |
Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US11091430 |
Recordation of Patent Grant Mailed
Critical
| 05 Mar, 2024 | US11919838 |
Patent eGrant Notification | 05 Mar, 2024 | US11919838 |
Mail Patent eGrant Notification | 05 Mar, 2024 | US11919838 |
Email Notification
Critical
| 05 Mar, 2024 | US11919838 |
Patent Issue Date Used in PTA Calculation
Critical
| 05 Mar, 2024 | US11919838 |
Recordation of Patent eGrant | 05 Mar, 2024 | US11919838 |
Email Notification
Critical
| 15 Feb, 2024 | US11919838 |
Issue Notification Mailed
Critical
| 14 Feb, 2024 | US11919838 |
Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US8124799 |
Reata Pharms's Family Patents
Reata Pharms Drug List
Given below is the complete list of Reata Pharms's drugs and the patents protecting them.
1. Skyclarys
Skyclarys is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8993640 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
24 Apr, 2033
(8 years from now)
| Active |
US9701709 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
24 Apr, 2033
(8 years from now)
| Active |
US8124799 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
03 Dec, 2029
(4 years from now)
| Active |
US11091430 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
20 Apr, 2029
(4 years from now)
| Active |
US11919838 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
20 Apr, 2029
(4 years from now)
| Active |
US8440854 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 |
20 Apr, 2029
(4 years from now)
| Active |
US9670147 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
20 Apr, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Skyclarys's drug page